African Sleeping Sickness News and Research RSS Feed - African Sleeping Sickness News and Research

African trypanosomiasis is also known as sleeping sickness. There are two types of African trypanosomiasis, East and West, named for the region of Africa in which they were historically found. People can get the disease if they are bitten by an infected tsetse fly, which is only found in Africa. Treatment is available for African trypanosomiasis, but it is fatal if left untreated.
Penn, UGA scientists awarded new contract to develop genome database for microbial pathogens

Penn, UGA scientists awarded new contract to develop genome database for microbial pathogens

At the turn of the millennium, the cost to sequence a single human genome exceeded $50 million, and the process took a decade to complete. Microbes have genomes, too, and the first reference genome for a malaria parasite was completed in 2002 at a cost of roughly $15 million. But today researchers can sequence a genome in a single afternoon for just a few thousand dollars. Related technologies make it possible to capture information about all genes in the genome, in all tissues, from multiple individuals. [More]
Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis). The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm. [More]
Researchers identify compounds that could lead to discovery of new drugs for African sleeping sickness

Researchers identify compounds that could lead to discovery of new drugs for African sleeping sickness

In early drug discovery, you need a starting point, says North­eastern Uni­ver­sity asso­ciate pro­fessor of chem­istry and chemical biology Michael Pollastri. [More]
Single dose restores normal cellular signaling in mouse model of autism

Single dose restores normal cellular signaling in mouse model of autism

In a further test of a novel theory that suggests autism is the consequence of abnormal cell communication, researchers at the University of California, San Diego School of Medicine report that an almost century-old drug approved for treating sleeping sickness also restores normal cellular signaling in a mouse model of autism, reversing symptoms of the neurological disorder in animals that were the human biological age equivalent of 30 years old. [More]
Protein M: an interview with Rajesh Grover, PhD, senior staff scientist, Lerner laboratory, TSRI

Protein M: an interview with Rajesh Grover, PhD, senior staff scientist, Lerner laboratory, TSRI

Protein M is a cell surface protein from Mycoplasma Genitalium that binds to all human antibodies. [More]
Researchers observe mating for the first time in microbes responsible for African sleeping sickness

Researchers observe mating for the first time in microbes responsible for African sleeping sickness

Caught in the act! Researchers from the University of Bristol have observed mating for the first time in the microbes responsible for African sleeping sickness. This tropical disease is caused by trypanosomes, single-celled parasites that are found in the blood of those afflicted. [More]

Study shows X-ray lasers can generate complete 3-D model of protein from scratch

A study shows for the first time that X-ray lasers can be used to generate a complete 3-D model of a protein without any prior knowledge of its structure. [More]
Furamidine drug may also be useful in treating cancers, immune-related diseases

Furamidine drug may also be useful in treating cancers, immune-related diseases

A class of drugs used to treat parasitic infections such as malaria may also be useful in treating cancers and immune-related diseases, a new WSU-led study has found. [More]
Genetic variations in African Americans with kidney disease contribute to rapid decline in kidney function

Genetic variations in African Americans with kidney disease contribute to rapid decline in kidney function

New research provides direct evidence that genetic variations in some African Americans with chronic kidney disease contribute to a more rapid decline in kidney function compared with white Americans. [More]
Researchers on the way to find cure against African sleeping sickness

Researchers on the way to find cure against African sleeping sickness

Researchers at Umeå University have identified drugs targeting infections of the parasite Trypanosoma brucei and are thereby well on the way to find a cure against African sleeping sickness. This is the kernel of a thesis, which will be publicly defended on 8 November 2013. [More]
Meclizine drug has the potential to treat certain infectious diseases and cancer

Meclizine drug has the potential to treat certain infectious diseases and cancer

Meclizine, an over-the-counter drug used for decades to treat nausea and motion sickness, has the potential for new uses to treat certain infectious diseases and some forms of cancer, according to Dr. Vishal M. Gohil, Texas A&M AgriLife Research biochemist. [More]
NIH awards 10 new grants to support genomics research in Africa

NIH awards 10 new grants to support genomics research in Africa

The National Institutes of Health has awarded 10 new grants totaling up to $17 million over the next four years to support genomics research in Africa, as part of the Human Heredity and Health in Africa (H3Africa) program [More]

University of Warwick professor wins Discovery STAR Award to identify new treatment for Chagas disease

Domainex Ltd., a drug discovery company specialising in translational research support, has announced that the recipient of its first Discovery STAR Award; Professor Vilmos Fulop of the University of Warwick. [More]
WHO includes new paediatric therapeutic options to EMLc

WHO includes new paediatric therapeutic options to EMLc

This week the World Health Organization released its newly updated 4th WHO Model List of Essential Medicines for Children, in which three treatments developed by the Drugs for Neglected Diseases initiative and its partners have now been included. [More]
New centre to boost development of drugs against TB, malaria and African sleeping sickness

New centre to boost development of drugs against TB, malaria and African sleeping sickness

A major new centre to boost the development of drugs to tackle the foremost diseases of the developing world is to be created at the University of Dundee. [More]
TU Darmstadt’s biosensor can diagnose African sleeping sickness before it breaks out

TU Darmstadt’s biosensor can diagnose African sleeping sickness before it breaks out

African sleeping sickness is an infectious disease that is widespread south of the Sahara Desert. Although the around sixty million people residing in tropical Africa run the risk of becoming infected with the disease every day, only around four million of them are monitored for the disease by disease-control authorities. [More]

'Greater commitment' needed to fight NTDs

In a guest post on USAID's "IMPACT Blog," Rachel Cohen, regional executive director of DNDi North America, writes, "The United States government and its country partners should be commended for the tremendous achievements in the fight against neglected tropical diseases (NTDs) as part of the U.S. Agency for International Development (USAID) NTD Program" and the National Institutes of Health. [More]
Microbiologists reveal how T. brucei’s key proteins organize to replicate its mtDNA

Microbiologists reveal how T. brucei’s key proteins organize to replicate its mtDNA

A group of diseases that kill millions of people each year can't be touched by antibiotics, and some treatment is so harsh the patient can't survive it. They're caused by parasites, and for decades researchers have searched for a "magic bullet" to kill them without harming the patient. Now, a team of microbiologists at the University of Massachusetts Amherst has made an advance that could one day lead to a new weapon for fighting parasitic diseases such as African sleeping sickness, chagas disease and leishmaniasis. [More]
Clemson researcher to continue African sleeping sickness study

Clemson researcher to continue African sleeping sickness study

Clemson University researcher James Morris received a $360,079 competitive renewal grant from the National Institutes of Health to continue his study of Trypanosoma brucei, the single-celled parasite that causes African sleeping sickness. [More]
Researchers identify fexinidazole as potential new therapy for visceral leishmaniasis

Researchers identify fexinidazole as potential new therapy for visceral leishmaniasis

Researchers at the University of Dundee have identified fexinidazole as a possible, much-needed, new treatment for the parasitic disease visceral leishmaniasis. [More]